Seattle
Genetics SGEN today announced that its collaborator, Millennium:
The Takeda Oncology Company, a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, announced that the European Commission
has granted conditional marketing authorization for ADCETRIS
(brentuximab vedotin). ADCETRIS was approved for two indications: (1)
the treatment of adult patients with relapsed or refractory
CD30-positive Hodgkin lymphoma (HL) following autologous stem cell
transplant (ASCT) or following at least two prior therapies when ASCT or
multi-agent chemotherapy is not a treatment option, and (2) for the
treatment of adult patients with relapsed or refractory systemic
anaplastic large cell lymphoma (sALCL). As a result, under the
collaboration Seattle Genetics will receive two milestone payments from
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in